Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

References

• SeidahNGBenjannetSWickhamLThe secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiationProc Natl Acad Sci U S A2003100392893312552133
   PubMed Web of Science ®Google Scholar
• NorataGDTavoriHPirilloAFazioSCatapanoALBiology of pro-protein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol loweringCardiovasc Res2016112142944227496869
   PubMed Web of Science ®Google Scholar
• IbarretxeDGironaJPlanaNCirculating PCSK9 in patients with type 2 diabetes and related metabolic disordersClin Investig Arterioscler20162827178
   PubMedGoogle Scholar
• ZhangLSongKZhuMProprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic strokeInt J Neurosci2016126867568026040332
   PubMed Web of Science ®Google Scholar
• FerdinandKCNasserSAPCSK9 Inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a)Cardiovasc Drugs Ther201529329530826068408
   PubMed Web of Science ®Google Scholar
• RaalFJGiuglianoRPSabatineMSPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s roleJ Lipid Res20165761086109627102113
   PubMed Web of Science ®Google Scholar
• RaalFJGiuglianoRPSabatineMSReduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsJ Am Coll Cardiol201463131278128824509273
   PubMed Web of Science ®Google Scholar
• JosephLRobinsonJGProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapyProg Cardiovasc Dis2015581193125936907
   PubMed Web of Science ®Google Scholar
• WeinreichMFrishmanWHAntihyperlipidemic therapies targeting PCSK9Cardiol Rev201422314014624407047
   PubMed Web of Science ®Google Scholar
• EverettBMSmithRJHiattWRReducing LDL with PCSK9 inhibitors–the clinical benefit of lipid drugsN Engl J Med2015373171588159126444323
   PubMed Web of Science ®Google Scholar
• LeporNEKereiakesDJThe PCSK9 inhibitors: a novel therapeutic target enters clinical practiceAm Health Drug Benefits20158948348926834934
   PubMedGoogle Scholar
• LipinskiMJBenedettoUEscarcegaROThe impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysisEur Heart J201637653654526578202
   PubMed Web of Science ®Google Scholar
• RobinsonJGFarnierMKrempfMEfficacy and safety of alirocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161489149925773378
   PubMed Web of Science ®Google Scholar
• RobinsonJGKasteleinJJPCSK9 inhibitors and cardiovascular eventsN Engl J Med20153738774
   PubMedGoogle Scholar
• SabatineMSGiuglianoRPWiviottSDEfficacy and safety of evolocumab in reducing lipids and cardiovascular eventsN Engl J Med2015372161500150925773607
   PubMed Web of Science ®Google Scholar
• ReinerZPCSK9 inhibitors–past, present and futureExpert Opin Drug Metab Toxicol201511101517152126329686
   PubMed Web of Science ®Google Scholar
• PecinIReinerZAlirocumab: targeting PCSK9 to treat hypercholesterolemiaDrugs Today (Barc)2015511268168726798848
   PubMed Web of Science ®Google Scholar
• NichollsSJPuriRAndersonTEffect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trialJAMA2016316222373238427846344
   PubMed Web of Science ®Google Scholar
• MercadoCDeSimoneAKOdomEGillespieCAyalaCLoustalotFPrevalence of cholesterol treatment eligibility and medication use among adults - United States, 2005–2012MMWR Morb Mortal Wkly Rep201564471305131126633047
   PubMed Web of Science ®Google Scholar
• SabatineMSGiuglianoRPKeechACEvolocumab and clinical outcomes in patients with cardiovascular diseaseN Engl J Med2017376181713172228304224
   PubMed Web of Science ®Google Scholar
• SaeedAViraniSSJonesPHNambiVZochDBallantyneCMA simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: a lipid clinic experienceJ Clin Lipidol201711359659928506382
   PubMed Web of Science ®Google Scholar
• GlueckCJShahPGoldenbergNEligibility for PCSK9 treatment in 734 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol >/=70 mg/dl despite maximal tolerated cholesterol lowering therapyLipids Health Dis20161515526968977
   PubMed Web of Science ®Google Scholar
• RothEMAlirocumab for hyperlipidemia: ODYSSEY phase III clinical trial results and US FDA approval indicationsFuture Cardiol201612211512826785741
   PubMed Web of Science ®Google Scholar
• SabatineMSWassermanSMSteinEAPCSK9 inhibitors and cardiovascular eventsN Engl J Med20153738774775
   PubMedGoogle Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• ShrankWHBarlowJFBrennanTANew therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelinesJAMA2015314141443144426258765
   PubMed Web of Science ®Google Scholar
• KaziDSMoranAEBibbins-DomingoKCost-effectiveness of PCSK9 inhibitor therapy-replyJAMA2016316202152
   PubMed Web of Science ®Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemiaScientific Steering Committee on behalf of the Simon Broome Register GroupBMJ199130368078938961933004
   PubMedGoogle Scholar
• RosensonRSBakerSKJacobsonTAKopeckySLParkerBAThe national lipid association’s muscle safety expertPAn assessment by the statin muscle safety task force: 2014 updateJ Clin Lipidol201483 SupplS58S7124793443
   PubMed Web of Science ®Google Scholar
• DaneshJCollinsRPetoRLipoprotein(a) and coronary heart disease. Meta-analysis of prospective studiesCirculation2000102101082108510973834
   PubMed Web of Science ®Google Scholar
• KamstrupPRTybjaerg-HansenANordestgaardBGLipoprotein(a) and risk of myocardial infarction–genetic epidemiologic evidence of causalityScand J Clin Lab Invest2011712879321231777
   PubMed Web of Science ®Google Scholar
• NordestgaardBGChapmanMJRayKLipoprotein(a) as a cardiovascular risk factor: current statusEur Heart J201031232844285320965889
   PubMed Web of Science ®Google Scholar
• SchreinerPJMorrisettJDSharrettARLipoprotein[a] as a risk factor for preclinical atherosclerosisArterioscler Thromb19931368268338499402
   PubMedGoogle Scholar
• ElshazlyMBMartinSSBlahaMJNon-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids)J Am Coll Cardiol201362211960196523973689
   PubMed Web of Science ®Google Scholar
• FryarCDChenTCLiXPrevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010NCHS Data Brief201210318
   PubMedGoogle Scholar
• TothPPPotterDMingEEPrevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003–2006J Clin Lipidol20126432533022836069
   PubMed Web of Science ®Google Scholar
• Abul-HusnNSManickamKJonesLKGenetic identification of familial hypercholesterolemia within a single U.S. health care systemScience20163546319aaf7000-1aaf7000-728008010
   PubMed Web of Science ®Google Scholar
• ReinerZManagement of patients with familial hypercholesterolaemiaNat Rev Cardiol2015121056557526076948
   PubMed Web of Science ®Google Scholar
• BennMWattsGFTybjaerg-HansenANordestgaardBGMutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the copenhagen general population study estimated a prevalence of 1 in 217Eur Heart J201637171384139426908947
   PubMed Web of Science ®Google Scholar
• WangJDronJSBanMRPolygenic versus monogenic causes of hypercholesterolemia ascertained clinicallyArterioscler Thromb Vasc Biol201636122439244527765764
   PubMed Web of Science ®Google Scholar
• KuklinaEVCarrollMDShawKMHirschRTrends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976–2010NCHS Data Brief201311718
   PubMedGoogle Scholar
• KnickelbineTLuiMGarberichRMiedemaMDStraussCVan-WormerJJFamilial hypercholesterolemia in a large ambulatory population: statin use, optimal treatment, and identification for advanced medical therapiesJ Clin Lipidol20161051182118727678435
   PubMed Web of Science ®Google Scholar
• HsiaSHDesnoyersMLLeeMLDifferences in cholesterol management among states in relation to health insurance and race/ethnicity across the United StatesJ Clin Lipidol20137667568224314367
   PubMed Web of Science ®Google Scholar
• MannDReynoldsKSmithDMuntnerPTrends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 national cholesterol education program guidelinesAnn Pharmacother20084291208121518648016
   PubMed Web of Science ®Google Scholar
• WatersDDBrotonsCChiangCWLipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsCirculation20091201283419546386
   PubMed Web of Science ®Google Scholar
• ZimmermanMPHow do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control?Am Health Drug Benefits20158843644226702335
   PubMedGoogle Scholar
• GlueckCJBudhaniSBMasineniSSVitamin D deficiency, myositis-myalgia, and reversible statin intoleranceCurr Med Res Opin20112791683169021728907
   PubMed Web of Science ®Google Scholar
• KhayznikovMHemachrandraKPanditRKumarAWangPGlueckCJStatin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementationN Am J Med Sci201573869325838999
   PubMed Web of Science ®Google Scholar
• SteinEARaalFJLipid-lowering drug therapy for CVD prevention: looking into the futureCurr Cardiol Rep2015171110426385394
   PubMed Web of Science ®Google Scholar
• ZhangXLZhuQQZhuLSafety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsBMC Med20151312326099511
   PubMed Web of Science ®Google Scholar
• HeidenreichPATrogdonJGKhavjouOAForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation2011123893394421262990
   PubMed Web of Science ®Google Scholar
• MilaniRVLavieCJImpact of worksite wellness intervention on cardiac risk factors and one-year health care costsAm J Cardiol2009104101389139219892055
   PubMed Web of Science ®Google Scholar
• ArenaRGuazziMBriggsPDPromoting health and wellness in the workplace: a unique opportunity to establish primary and extended secondary cardiovascular risk reduction programsMayo Clin Proc201388660561723726400
   PubMed Web of Science ®Google Scholar
• GroverSAHoVLavoieFCoupalLZowallHPiloteLThe importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?Arch Intern Med2003163333333912578514
   PubMedGoogle Scholar